Featured Research

from universities, journals, and other organizations

Molecular Insight Into How A Heart Failure Drug In Clinical Trials Works

Date:
January 16, 2009
Source:
Journal of Clinical Investigation
Summary:
Individuals who have persistent high blood pressure are at increased risks of a number of serious medical conditions, including heart failure. One of the factors that contributes to such heart failure is thickening of the muscle wall of the heart.

Individuals who have persistent high blood pressure are at increased risks of a number of serious medical conditions, including heart failure. One of the factors that contributes to such heart failure is thickening of the muscle wall of the heart.

Such thickening (known as hypertrophy) is a compensatory response of the heart to the high blood pressure.

A team of researchers at Johns Hopkins University, Baltimore, has provided new insight into both the signaling mechanisms by which high blood pressure leads to compensatory hypertrophy of the mouse heart and the molecular mechanisms by which a heart failure drug in clinical trials works.

In the study, which was led by Eiki Takimoto and David Kass, when mice lacking the protein RGS2 were manipulated such that they had persistent high blood pressure they developed hypertrophy of the muscle wall of the heart more rapidly than normal mice manipulated in the same way.

Further, these mice went on to exhibit heart failure and died at a young age. Additional analysis indicated that a drug that prevents hypertrophy by targeting the protein PDE5 was less effective at preventing hypertrophy caused by high blood pressure in RGS2-deficient mice than in normal mice.

These data have clinical implications, as they provide insight into the mechanism by which PDE5 inhibitors, which have recently entered clinical trials to treat a form of heart failure, work.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. Journal of Clinical Investigation, Jan 6, 2009

Cite This Page:

Journal of Clinical Investigation. "Molecular Insight Into How A Heart Failure Drug In Clinical Trials Works." ScienceDaily. ScienceDaily, 16 January 2009. <www.sciencedaily.com/releases/2009/01/090105175023.htm>.
Journal of Clinical Investigation. (2009, January 16). Molecular Insight Into How A Heart Failure Drug In Clinical Trials Works. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2009/01/090105175023.htm
Journal of Clinical Investigation. "Molecular Insight Into How A Heart Failure Drug In Clinical Trials Works." ScienceDaily. www.sciencedaily.com/releases/2009/01/090105175023.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins